Recently, we described a patient with severe lactic acidosis due to congenital complex I (NADH-ubiquinone oxidoreductase) deficiency. We now report further enzymatic and immunological characterizations. Both NADH and ferricyanide titrations of complex I activity (measured as NADH-ferricyanide reductase) were distinctly altered in the mitochondria from the patient's tissues. In addition, antisera against complex I immunoprecipitated NADH-ferricyanide reductase from the control but not the patient's mitochondria. However, immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis of complex I polypeptides demonstrated that the majority of the 25 polypeptides comprising complex I were present in the affected mitochondria. A more detailed analysis using subunit selective antisera against the main polypeptides of the iron-protein fragments of complex I revealed a selective absence of the 75-and 13-kD polypeptides. These findings suggest that the underlying basis for this patient's disease was a congenital deficiency of at least two polypeptides comprising the iron-protein fragment of complex I, which resulted in the inability to correctly assemble a functional enzyme complex.
Introduction
The terms "mitochondrial myopathy" have been used to describe a heterogeneous group of metabolic diseases and are often characterized by morphologic alterations ofmitochondria in skeletal muscle. However, morphologic criteria alone are unsatisfactory, since not all mitochondrial abnormalities manifest themselves in altered morphology; moreover, it is unclear in many cases whether morphologic changes represent the primary defect or are secondary to some other metabolic consequence. Since the original description of a mitochondrial disease by Luft et al. (1) in 1962, several lesions involving distinct segments of the mitochondrial electron transport chain have been described. Specific defects in complex I (NADH-ubiquinone oxidoreductase) (2-7), complex II (succinate-ubiquinone oxidoreductase) (8) , complex III (ubiquinol-cytochrome c oxidoreductase) (9, 10) , and complex IV (cytochrome c oxidase) (11) (12) (13) (14) (15) , as well as in t Deceased. complex V (F0FIATPase) (16) , have been reported. In these investigations, enzyme activities, spectrophotometric analysis of electron carriers, and/or electron paramagnetic resonance (EPR)' measurements were used to define the nature of the lesions. Recently, Darley-Usmar et al. (10) used specific antisera to demonstrate the absence of certain of the polypeptide subunits of complex III, thus providing a new approach to the investigation of these mitochondrial diseases.
In an earlier paper (2) we reported clinical and biochemical studies on an infant with severe congenital lactic acidosis. Investigations of mitochondria isolated from muscle biopsy and tissues obtained at atuopsy revealed defective NAD-linked electron transport due to a specific deficiency in complex I activity. This was shown to result from the near total absence ofthe EPRdetectable iron-sulfur centers characteristic of complex I; the other iron-sulfur centers ofthe mitochondria, particularly those of complexes II and III, were normal. We postulated that this may result from an absence or genetic alteration in one or more ofthe 25 polypeptides comprising complex I, some ofwhich are involved in the molecular organization and function of the ironsulfur centers (17) . This study demonstrates further enzymatic and immunologic characterization ofthe patient's mitochondria. Our results reveal distinct abnormalities in the kinetics of the NADH-ferricyanide oxido-reductase portion of complex I, as well as complete absence of the 75-and 13-kD polypeptides normally present in the iron-sulfur protein (IP) fraction ofcomplex I. The data suggest the lack of these polypeptides results in incomplete or incorrect assembly of a functional complex I.
Methods
Preparation of mitochondria. Liver and heart mitochondria, as well as submitochondrial particles (SMPs) from the affected patient and from normal human tissues used as controls, were isolated and stored at -700C as described previously (2, 18). Samples for study were thawed under warm tap water, placed on ice, and used within 2 h. Kinetic analysis ofcomplex L NADH and ferricyanide titrations of complex I activity were determined as follows: frozen liver SMPs and heart mitochondria were thawed and diluted to 1 mg/ml in ice-cold 1% Triton X-100, 0.25 M sucrose, and 50 mM Tris-HCI at pH 8.0. Kinetic studies were conducted using variable concentrations of ferricyanide (0.125-2.5 mM) at a fixed concentration of 0.15 mM NADH, and variable NADH concentrations (3.5-100 M) at a fixed concentration of0.10 mM ferricyanide. Reactions were initiated by addition of solubilized mitochondria to the complete incubation mixture after thermal equilibration. The nonenzymatic rate offerricyanide reduction was subtracted from the initial enzymatic rate. The rate of ferricyanide reduction was measured in a final volume of 1.0 ml at 410 nm in 40 mM friethanolamine buffer at pH 7.8 and 30'C.
Immunoprecipitation ofNADH-ferricyanide reductase activityfrom solubilized liver mitochondria. Samples of beef heart SMPs and liver (or heart) mitochondria from the patient and control tissues were prepared for immunoprecipitation by diluting the freeze-thawed stock samples into ice-cold 1% Triton X-100, 0.5% sodium deoxycholate, 0.5 M KCl, 0.25 M sucrose, and 50 mM Tris-HCl at pH 8.0 at a final protein concentration of 1 mg/ml. Aliquots were then removed and diluted to a final protein concentration of 0.4 mg/ml in the same buffer containing variable quantities of antiholocomplex I antiserum or preimmune serum (final volume, 0.5 ml). After incubation on ice for 1 h the samples were centrifuged at 25,000 rpm (50,000 g) for 30 min at 4VC and the supernatant fractions were carefully removed and assayed for NADH-ferricyanide reductase activity in a buffer containing 1 mM ferricyanide, 0.21 mM NADH, and 20 mM potassium phosphate at pH 8.0 and 30'C. The final volume was 1.1 ml and ferricyanide reduction was followed at 410 nm.
Immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) profiles using antiholocomplex I antisera.
Samples for immunoprecipitation were thawed and prepared as described in (19) , except that incubation with antiserum (0.4 ml/mg of mitochondria) was carried out for only 4 h at 0°C. The immunoprecipitate (derived from 2 mg mitochondrial protein) was dissolved in 1% SDS and 4% 2-mercaptoethanol in a final volume of 100 ,ul, and 20-,ul aliquots were applied to a linear 12.5-16% gradient gel, electrophoresed, and stained according to Laemmli (20) . The protease inhibitor, p-aminobenzamidine, was present at 5 mM final concentration in all stages except the final solubilization in SDS. Molecular weight standards were obtained from Sigma and British Drug Houses, Poole, U. K.
Western blot analysis using specific antisera to IPfragment polypeptides. Freeze-thawed mitochondria from the patient and beef heart were pretreated with 5 mM p-aminobenzamidine for 10 min at 4°C, then solubilized in 1% SDS wt/vol and 1% 2-mercaptoethanol vol/vol. Approximately 50 ,g of protein was applied to a linear SDS-PAGE (polyacrylamide gradient gel, 12.5-16% wt/vol) and electrophoresed at room temperature using the discontinuous buffer system described by Laemmli (20) . Proteins were electrophoretically transferred at constant 30 V to nitrocellulose sheets in a buffer containing 25 mM Tris-HCl, 0.19 M glycine, 20% methanol vol/vol at pH 8.0 for 3 h at 4VC. The nitrocellulose sheets were then saturated with standard phosphate-buffered saline containing 0.5% bovine serum albumin (SIGMA, fraction V) and 0.04% sodium azide (PBS-BSA) at room temperature with continuous shaking overnight. The sheets were subsequently incubated with subunit selective antisera against the four main subunits of the IP fragment (75-, 49-, 30-and 1 3-kD polypeptides) or anti-complex I antisera (1:200 dilutions at 37°C for 1.5 h) and rinsed with PBS-BSA for 1.5 h (at 37°C with continuous shaking). This buffer was decanted and an equal volume of PBS-BSA buffer containing '251labeled protein A (0.5 X 106 counts/ml, 15 Ml protein A per 10 ml of buffer) was added and shaken for an additional hour at 37°C. The nitrocellulose sheet was then removed, rinsed three times with distilled water, blotted dry, and allowed to completely air dry using a low speed blower. Autoradiography was performed using Kodak XOMAT-S film at -70°C for 24-48 h with the aid of a Cronex lightningplus intensifying screen (DuPopt Instruments, Wilmington, DE).
Results
Kinetic characterization ofNADH-ferricyanide reductase activity ofcomplex L In the previous investigation (2) we reported that NADH-ferricyanide reductase activity in the patient's mitochondria was normal, when compared with similar assays on normal human mitochondria. However, the overall NADHubiquinone oxido-reductase activity of the patient's mitochondria was essentially zero. This led us to suspect that the defect in complex I was localized exclusively in its iron-sulfur centers, which are required for reduction of ubiquinone. In these earlier tests NADH-ferricyanide activity was assayed using single fixed concentrations of NADH (Fig. 1) . Similar results were obtained for variable ferricyanide at a fixed NADH concentration (Fig. 2) . At concentrations of ferricyanide exceeding -1.5 mM, a profound inhibition of activity occurred in both the patient and the control; this is caused by competition of ferricyanide with NADH. Thus, the original observation showing identical NADH-ferricyanide reductase activities at a fixed concentration ofNADH and of ferricyanide must now be interpreted in light of these newer findings, which suggests: (a) an alteration in the enzymatic activity of complex I in the patient, manifest as a kinetic difference, or (b) a separate NADH-ferricyanide reductase activity in mitochondria or contaminating particles together with an absence of NADH-ferricyanide reductase activity attributable to complex I in the patient.
Immunoprecipitation of NADH-ferricyanide reductase activity. The kinetic studies raised the possibility that there may be a virtual absence of complex I altogether in the patient's mitochondria, since we could not identify a kinetically similar NADH-ferricyanide reductase activity comparable with the control. To address this possibility, we attempted to immunoprecipitate NADH-ferricyanide reductase activity using antiholocomplex I antisera known to immunoprecipitate NADH-ferricyanide reductase activity from beef heart SMPs (21). The results are shown in Fig. 3 . Antiserum prepared against beef heart complex I also immunoprecipitates NADH-ferricyanide reductase activity from human liver (and heart, data not shown) mitochondria. In the experiment using control human liver mitochondria, 65% of the NADH-ferricyanide reductase activity is immunoprecipitated, but no NADH-ferricyanide reductase activity was immunoprecipitated from the patient's liver mitochondria at any concentration of antisera. Multiple batches of antiholocomplex I antisera from several different preparations of beef heart complex I were used and none of the antisera immunoprecipitated NADH-ferricyanide reductase activity from the patient.
The (Fig. 4) contain the immunoprecipitated human material. Lane 4 represents normal human kidney mitochondria; note the resemblance to native complex I from beef heart. Unfortunately, the presence ofimmunoglobulins obscures the region from 45-65 kD and prevents a detailed comparison of subunits there. However, the most remarkable results were obtained in lanes 5 and 6. Lane 5 represents normal human liver mitochondria, and again is very similar to beef heart and virtually identical to normal kidney. Lane 6 contains the patient's mitochondria, and, surprisingly, the majority of complex I was present. Based on crude staining properties, roughly the same amount of the major subunits was present for both the normal and patient's liver mitochondria. There were some differences present, notably the near absence of a band at 75 kD in the patient's liver mitochondria, and possibly others at 39 kD, 21 kD, and 13 kD. Limited material precluded additional studies on heart or skeletal muscle mitochondria.
Although these results are highly suggestive that there may be polypeptide deficiencies in the patient's complex I, they are not conclusive. Nonetheless, several important points are apparent: (a) there is a remarkable similarity between the human and bovine enzyme, a result that adds to our comparative knowledge on the structure ofcomplex I; (b) the identical nature of the enzyme in both normal human liver and kidney; and (c) the presence ofa highly integrated, immunoprecipitable complex in the patient's liver mitochondria present in amounts similar to the control but devoid of both ubiquinone reductase (NADH coenzyme Q) and ferricyanide reductase activity.
Western blot analysis of the IPfragment polypeptides. The results shown in Fig. 4 documented common antigenic sites in complex I from beef heart, human, liver, and kidney mitochondria. Thus, we had reason to suspect that subunit-specific antisera might also cross-react with complex I from both sources. Furthermore, based on the EPR results reported in (2), we anticipated that the iron-sulfur clusters would be the most likely candidates for a primary alteration in subunits. Fig. 5 shows the results obtained when subunit-specific antisera generated against the purified 75-, 49-, 30-, and 13-kD polypeptides ofthe IP fragment of complex I were used to immunoblot SDS-separated polypeptides from the patient and control. Whole heart and liver mitochondria as well as beef heart SMPs were used in this experiment. As shown in lane 3 (Fig. 5) , four major subunits are identified in beef heart SMPs. Likewise, similar polypeptides, with slightly different relative molecular masses, were identified in mitochondria from the control heart (lane 1) and control liver (lane 4). However, both the 75-and, 13 -kD polypeptides were absent in the mitochondria from both the heart and liver of the patient (lanes 2 and 5, respectively). In addition, there is a definite indication, based on intensity of staining, of reduced amounts of the 49-and 30-kD polypeptides in the affected mitochondria. species in both the beef heart SMPs and human control mitochondria (data not shown). These observations demonstrate several points: (a) the major polypeptides of the IP fragment of human complex I cross-react with antisera raised against those of beef heart, and are similar in molecular weight; (b) the 75-and 1 3-kD polypeptides are lacking in human liver and heart mitochondria from the patient; and (c) there are reduced amounts of the remaining IP fragment polypeptides, 49 
Discussion
In a previous study, we identified a patient who had deficient complex I activity in four separate tissues due to an absence of the characteristic iron-sulfur clusters detected by EPR (2). In the present study, we have extended those observations to a more detailed molecular level. Using specific enzymatic and immunological techniques we have identified the absence of two of the polypeptide constituents of the IP fragment of complex I in the patient's mitochondria. We propose the underlying molecular basis for this patient's severe lactic acidosis resulted from the absence of (at least) the 75-and 1 3-kD pdlypeptides. Their absence likely results in an inability to correctly assemble either the entire polypeptide complex or, possibly, an inability to incorporate iron into a stable and functional iron-sulfur cluster, thus resulting in an inability for electron transfer to occur from NADH to ubiquinone.
Our initial observations regarding the presence of identical NADH-ferricyanide reductase activities in the patient and control, a result which led us to investigate the iron-sulfur centers by EPR, has now been shown to be incorrect but fortuitous. It is clear that a complete kinetic titration of the NADH-ferricyanide reductase activity must be used instead of a single fixed concentration of substrates. (10) .
Another intriguing aspect of our work relates to the mode of inheritance. The parents of the infant studied here showed no family history of lactic acidosis or muscle defect, and they have subsequently had a normal male child. Thus, if the lesion was transmitted via the mitochondrial genome, one would predict all children would be affected, since mitochondria are of maternal inheritance. It appears more likely that the genetic defect is autosomally recessive or was the result of a spontaneous lethal mutation. Therefore, we presume the genetic defect is one that either involves the nuclear transcription (or translation) of the 75-and 13-kD polypeptides, or involves the transport of these polypeptides (or others) into the mitochondria or to the site of assembly of complex I. The demonstration of a distinct abnormality in this case by use of subunit selective antibodies may allow prenatal diagnosis using either amniocytes or chorionic villi.
